For several years, therapeutic research in AD and PD was centered in targeting insoluble fibrillar aggregates of Aβ, tau and αSyn, but recent studies have shown that soluble oligomers are the most toxic species that induce neuronal damage and dysfunction in neurodegenerative disorders [27,28,29,30,31,32,33,34,35,36], suggesting that anti-oligomeric therapeutic strategies would be a better approach to antagonize cognitive deficit symptoms. This evidence concerns the gene MAPT and Cognitive impairment.